R S Isaacson1, N Haynes1, A Seifan2, D Larsen3, S Christiansen1, J C Berger1, J E Safdieh1, A M Lunde4, A Luo1, M Kramps1, M McInnis5, C N Ochner6. 1. Weill Cornell Medical College, New York, NY. 2. Columbia University College of Physicians and Surgeons, New York, NY. 3. Washington University School of Medicine, St. Louis, MO. 4. Mayo Clinic, Rochester, MN. 5. Wishbone Productions, Boston, MA. 6. Icahn School of Medicine at Mount Sinai, New York, NY.
Abstract
BACKGROUND:Internet-based educational interventions may be useful for impacting knowledge and behavioral change. However, in AD prevention, little data exists about which educational tools work best in terms of learning and interest in participating in clinical trials. OBJECTIVES: Primary: Assess effectiveness of interactive webinars vs. written blog-posts on AD prevention learning. Secondary: Evaluate the effect of AD prevention education on interest in participating in clinical trials; Assess usability of, and user perceptions about, an online AD education research platform; Classify target populations (demographics, learning needs, interests). DESIGN: Observational. SETTING: Online. PARTICIPANTS: Men/Women, aged 25+, recruited via facebook.com. INTERVENTION: Alzheimer's Universe (www.AlzU.org) education research platform. MEASUREMENTS: Pre/post-test performance, self-reported Likert-scale ratings, completion rates. RESULTS: Over two-weeks, 4268 visits were generated. 503 signed-up for a user account (11.8% join rate), 196 participated in the lessons (39.0%) and 100 completed all beta-testing steps (19.9%). Users randomized to webinar instruction about AD prevention and the stages of AD demonstrated significant increases (p=0.01) in pre vs. post-testing scores compared to blog-post intervention. Upon joining, 42% were interested in participating in a clinical trial in AD prevention. After completing all beta-test activities, interest increased to 86%. Users were primarily women and the largest category was children of AD patients. 66.3% joined to learn more about AD prevention, 65.3% to learn more about AD treatment. CONCLUSIONS: Webinar-based education led to significant improvements in learning about AD prevention and the stages of AD. AlzU.org participation more than doubled interest in AD prevention clinical trial participation. Subjects were quickly and cost-effectively recruited, and highly satisfied with the AD education research platform. Based on these data, we will further refine AlzU.org prior to public launch and aim to study the effectiveness of 25 interactive webinar-based vs. blog-post style lessons on learning and patient outcomes, in a randomized, within-subjects design trial.
RCT Entities:
BACKGROUND: Internet-based educational interventions may be useful for impacting knowledge and behavioral change. However, in AD prevention, little data exists about which educational tools work best in terms of learning and interest in participating in clinical trials. OBJECTIVES: Primary: Assess effectiveness of interactive webinars vs. written blog-posts on AD prevention learning. Secondary: Evaluate the effect of AD prevention education on interest in participating in clinical trials; Assess usability of, and user perceptions about, an online AD education research platform; Classify target populations (demographics, learning needs, interests). DESIGN: Observational. SETTING: Online. PARTICIPANTS: Men/Women, aged 25+, recruited via facebook.com. INTERVENTION: Alzheimer's Universe (www.AlzU.org) education research platform. MEASUREMENTS: Pre/post-test performance, self-reported Likert-scale ratings, completion rates. RESULTS: Over two-weeks, 4268 visits were generated. 503 signed-up for a user account (11.8% join rate), 196 participated in the lessons (39.0%) and 100 completed all beta-testing steps (19.9%). Users randomized to webinar instruction about AD prevention and the stages of AD demonstrated significant increases (p=0.01) in pre vs. post-testing scores compared to blog-post intervention. Upon joining, 42% were interested in participating in a clinical trial in AD prevention. After completing all beta-test activities, interest increased to 86%. Users were primarily women and the largest category was children of ADpatients. 66.3% joined to learn more about AD prevention, 65.3% to learn more about AD treatment. CONCLUSIONS: Webinar-based education led to significant improvements in learning about AD prevention and the stages of AD. AlzU.org participation more than doubled interest in AD prevention clinical trial participation. Subjects were quickly and cost-effectively recruited, and highly satisfied with the AD education research platform. Based on these data, we will further refine AlzU.org prior to public launch and aim to study the effectiveness of 25 interactive webinar-based vs. blog-post style lessons on learning and patient outcomes, in a randomized, within-subjects design trial.
Authors: Bruno Vellas; Alain Pesce; Philippe H Robert; Paul S Aisen; Sonia Ancoli-Israel; Sandrine Andrieu; Jesse Cedarbaum; Bruno Dubois; Eric Siemers; Jean-Paul Spire; Michael W Weiner; Thomas S May Journal: Alzheimers Dement Date: 2011-07 Impact factor: 21.566
Authors: Mary Sano; Susan Egelko; Michael Donohue; Steven Ferris; Jeffrey Kaye; Tamara L Hayes; James C Mundt; Chung-Kai Sun; Silvia Paparello; Paul S Aisen Journal: Alzheimer Dis Assoc Disord Date: 2013 Oct-Dec Impact factor: 2.703
Authors: J Harris; L Felix; A Miners; E Murray; S Michie; E Ferguson; C Free; K Lock; J Landon; P Edwards Journal: Health Technol Assess Date: 2011-10 Impact factor: 4.014
Authors: Richard S Isaacson; Hollie Hristov; Nabeel Saif; Katherine Hackett; Suzanne Hendrix; Juan Melendez; Joseph Safdieh; Matthew Fink; Madhav Thambisetty; George Sadek; Sonia Bellara; Paige Lee; Cara Berkowitz; Aneela Rahman; Josefina Meléndez-Cabrero; Emily Caesar; Randy Cohen; Pei-Lin Lu; Samuel P Dickson; Mu Ji Hwang; Olivia Scheyer; Monica Mureb; Matthew W Schelke; Kellyann Niotis; Christine E Greer; Peter Attia; Lisa Mosconi; Robert Krikorian Journal: Alzheimers Dement Date: 2019-10-31 Impact factor: 21.566
Authors: Richard S Isaacson; Alon Seifan; Candace L Haddox; Monica Mureb; Aneela Rahman; Olivia Scheyer; Katherine Hackett; Emily Caesar; Jaclyn L Chen; Jon Isaacson; Mark McInnis; Lisa Mosconi; Joseph Safdieh Journal: J Commun Healthc Date: 2018-05-05
Authors: Richard S Isaacson; Christine A Ganzer; Hollie Hristov; Katherine Hackett; Emily Caesar; Randy Cohen; Robert Kachko; Josefina Meléndez-Cabrero; Aneela Rahman; Olivia Scheyer; Mu Ji Hwang; Cara Berkowitz; Suzanne Hendrix; Monica Mureb; Matthew W Schelke; Lisa Mosconi; Alon Seifan; Robert Krikorian Journal: Alzheimers Dement Date: 2018-11-13 Impact factor: 21.566
Authors: Edward Meinert; Jessie Eerens; Christina Banks; Stephen Maloney; George Rivers; Dragan Ilic; Kieran Walsh; Azeem Majeed; Josip Car Journal: JMIR Med Educ Date: 2021-03-11
Authors: Cara L Berkowitz; Lisa Mosconi; Olivia Scheyer; Aneela Rahman; Hollie Hristov; Richard S Isaacson Journal: Healthcare (Basel) Date: 2018-07-13